TJX Companies Inc (TJX) Stock Price Today
Aura AI Summary
Key Stats
- $179.03BMarket Cap
- -Volume
- Consumer CyclicalSector
- $168.4152W High
- $131.3752W Low
- -Typical Hold Time
- $187.63BEnterprise Value
- 1.18%Div Yield
- -Trading Activity
Track TJX Companies Inc (TJX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, TJX Companies Inc has traded between a low of $131.37 and a high of $168.41, highlighting its annual price range. Buy and sell TJX Companies Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Most Recent News
Vistra misses Q3 earnings estimates due to $472M hedge loss but core operations show strong 30% EBITDA growth.
Vistra Corp reported Q3 earnings per share of $1.68, below the expected $2.43, and revenue of $5 billion, missing the $5.46 billion forecast. The shortfall was mainly caused by a $472 million unrealized loss from commodity hedges. Despite this, Vistr...
2026 National ORBIE Awards honor top CIOs and CISOs across key industry categories in San Jose.
The 2026 National ORBIE Awards recognized outstanding leadership among chief information officers (CIOs) and chief information security officers (CISOs) across 11 categories, celebrating executives from major global and enterprise organizations. Winn...
Replimune's melanoma drug gets FDA nod but faces legal probe over data practices
Replimune Group's melanoma drug Tudriqev received accelerated FDA approval after two prior rejections, based on a 24.20% response rate in trials. Following this, BMO Capital raised its price target for Replimune stock from $16 to $20, indicating stro...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.